Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Barlogie

Showing results (11-20 of 330) with videos related to

Pageof 33
Sort By:
Immunological Reviews|July 9, 2003
Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profilingJohn D Shaughnessy, Bart Barlogie
Ultrastructural Pathology|February 27, 2008
Morphologic heterogeneity of renal light-chain deposition diseaseNeriman Gokden, Bart Barlogie, Helen Liapis
Statistics in Medicine|June 19, 2015
Using a latent class model to refine risk stratification in multiple myelomaPingping Qu, Bart Barlogie, John Crowley
Seminars in Hematology|October 29, 2003
Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profilingFenghuang Zhan, Bart Barlogie, John Shaughnessy
The New England Journal of Medicine|July 11, 2008
Duration of survival in patients with myeloma treated with thalidomideBart Barlogie, John D Shaughnessy, John Crowley
Haematologica|November 5, 2013
Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145Xenofon Papanikolaou, Christoph J Heuck, Bart Barlogie
Blood|June 5, 2014
The future of autologous stem cell transplantation in myelomaFrits van Rhee, Sergio Giralt, Bart Barlogie
British Journal of Haematology|March 16, 2004
Treatment advances in multiple myelomaGuido Tricot, Bart Barlogie, Frits Van Rhee
Blood|November 8, 2008
Going with the flow, and beyond, in myelomaBart Barlogie, Joshua Epstein, John D Shaughnessy
The New England Journal of Medicine|September 26, 2008
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2Bart Barlogie, John D Shaughnessy, John Crowley
Pageof 33

Showing results (11-20 of 330) with videos related to

Sort By:
Pageof 33
Immunological Reviews|July 9, 2003
Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profilingJohn D Shaughnessy, Bart Barlogie
Ultrastructural Pathology|February 27, 2008
Morphologic heterogeneity of renal light-chain deposition diseaseNeriman Gokden, Bart Barlogie, Helen Liapis
Statistics in Medicine|June 19, 2015
Using a latent class model to refine risk stratification in multiple myelomaPingping Qu, Bart Barlogie, John Crowley
Seminars in Hematology|October 29, 2003
Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profilingFenghuang Zhan, Bart Barlogie, John Shaughnessy
The New England Journal of Medicine|July 11, 2008
Duration of survival in patients with myeloma treated with thalidomideBart Barlogie, John D Shaughnessy, John Crowley
Haematologica|November 5, 2013
Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145Xenofon Papanikolaou, Christoph J Heuck, Bart Barlogie
Blood|June 5, 2014
The future of autologous stem cell transplantation in myelomaFrits van Rhee, Sergio Giralt, Bart Barlogie
British Journal of Haematology|March 16, 2004
Treatment advances in multiple myelomaGuido Tricot, Bart Barlogie, Frits Van Rhee
Blood|November 8, 2008
Going with the flow, and beyond, in myelomaBart Barlogie, Joshua Epstein, John D Shaughnessy
The New England Journal of Medicine|September 26, 2008
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2Bart Barlogie, John D Shaughnessy, John Crowley
Pageof 33